1500 E Med Center Dr
Ann Arbor, MI 48109-5378
Available to mentor
Sarah Kurz, MD is a Clinical Assistant Professor of Medicine at the University of Michigan Medical School. Clinically, she works in adult Infectious Diseases where she has particular interests in HIV, endocarditis, sexually transmitted infections, and caring for patients who have co-morbid substance use.
She earned her degree in medicine from the University of Michigan Medical School and completed residency in Internal Medicine and fellowship in Infectious Diseases at the University of Pennsylvania (Penn). While at Penn, she completed a fellowship in medical education.
She enjoys reading, running, playing with her dog, and spending times with friends and family.
-
FellowshipHospital of the University of Pennsylvania, Philadelphia, 2022
-
Internship and ResidencyHospital of the University of Pennsylvania, Philadelphia, 2020
-
M.D.University of Michigan Medical School, 2017
-
B.A.University of Pennsylvania, 2013
•Clinical Coaching
•Multidisciplinary approaches to treating patients who inject drugs
-
Kurz S, Abernethy JL, Tate S, Shalaby M, Chertok J, Nandiwada DR. SGIM Forum, 2024 Jun 4; 46 (3): 7 - 7.Journal ArticleDeveloping a Medication for the Opioid Use Disorder Workforce in Primary Care Training
-
Howard R, Kurz S, Sherman MA, Underhill J, Eliason JL, Coleman DM. Annals of Vascular Surgery, 2015 Jan 1; 29 (8): 1614 - 1618.Journal ArticleContemporary Management of Secondary Aortoduodenal Fistula
DOI:10.1016/j.avsg.2015.06.090 PMID: 26318554 -
Howard R, Kurz S, Sherman M, Underhill J, Eliason J, Coleman DM, Howard presenter R. 2015 Jan 1;Proceeding / Abstract / PosterContemporary Management of Secondary Aortoduodenal Fistula
-
Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, Ng KK, Dutta PR, Gelblum DY, Lee JL, Shen R, Kurz S, Katabi N, Haque S, Lee NY, Pfister DG. Ann Oncol, 2024 Jun 4; 25 (3): 689 - 694.Journal ArticlePhase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).
DOI:10.1093/annonc/mdt579
